Megan Holdings Limited, a Malaysian aquaculture company, completed a $7.5 million follow-on public offering by selling 15 million Class A shares at $0.50 each. The funds raised will support business ventures, acquisitions, and general working capital to expand its aquaculture farm development and maintenance services. The offering was managed by Prime Number Capital and registered with the SEC. This capital raise aims to strengthen Megan's position in the shrimp farming industry in Malaysia and support ongoing projects like shrimp hatchery and farm developments.
Megan Holdings Limited's recent $7.5 million follow-on offering provides context for market activity. For readers following Basic Materials, here is Pluang's market snapshot as of Oct 29, 2026 21:03 WIB: Among 83 priced US stocks, 27 rose and 56 fell. Notable movers include SQM at USD 56.73 with a -3.75% change, IAG at USD 16.64 down 3.70%, and SSRM at USD 28.59 down 3.67%.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
